anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Licogliflozin
Trial phase: Phase 2
SMILES: CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Matching placebo tablets tid before meals.
Eligibility criteria:
Key Inclusion Criteria:

Subjects with stable health condition as determined by past medical history, physical examination, electrocardiogram, and laboratory tests at screening.
Patients with dysglycemia are patients with: Fasting plasma glucose >100mg/dL (5.6 mmol/L), or HbA1c > 5.7% and < 10% at screening.
Fasting plasma glucose ≤250mg/dL (13.9 mmol/L) at screening.
If treated with antidiabetic medications (other than prohibited medications), patients must be on a stable dose for 12 weeks prior to randomization and maintain the dose until the end of the study.
Subjects must have a body mass index (BMI) within the range of 35 - 50 kg/m2 at screening, with stable body weight (± 5 kg) within 3 months prior to screening

Key Exclusion Criteria:

Pre-existing, clinically significant gastrointestinal, liver, cardiovascular, renal or other chronic medical condition which is considered serious or unstable, other than stable cardiovascular disease, treated hypertension, dyslipidemia or other stable chronic disorders
Clinically significant GI disorder related to malabsorption or that may affect drug or glucose absorption or history of significant gastrointestinal surgery that could affect intestinal glucose absorption
Enrollment in a diet, weight loss or exercise programs with the specific intent of losing weight, within 3 months prior to randomization, or clinical diagnosis of any eating disorder
Pregnant or nursing (lactating) women, and women of child-bearing potential
Intervention: Rifaximin
Trial phase: Phase 2 | Phase 3
ATC code: A07AA11 | D06AX11
SMILES: COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Participants in this group received a 7-day treatment with Rifaximin and were followed for three months. Participants were blinded to their treatment assignment until the conclusions of the 3-month visit.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of idiopathic PD
Daily "off" time ≥ 4 hours
No changes in levodopa or any other dopaminergic medications expected during the course of the study
Will be screened for cognitive ability (Montreal Cognitive Assessment score of ≥ 24) prior to enrollment
Will be screened for presence of SIBO prior to enrollment

Exclusion Criteria:

Any comorbid non-PD-associated gastrointestinal (e.g., achlorhydria) or systemic diseases that may alter absorption or confound the study results
Exposure to proton pump inhibitors, immunosuppressive drugs, medications that affect GI motility (such as prokinetics, anticholinergics, and tricyclic antidepressants), antibiotics or any other drugs that affect the intestinal flora (such as laxatives) within a month prior to enrollment.
Prior deep brain stimulation or ablative functional neurosurgery.
Prior allergy to rifaximin
Women who are pregnant, lactating, or plan to become pregnant.
Intervention: Panobinostat
Trial phase: Phase 1 | Phase 2
ATC code: L01XH03 | L01XX42
SMILES: Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Participants in Arm A will receive panobinostat as an oral tablet on days 0, 2, and 4 of the treatment week. The dose of panobinostat will be a 15 mg tablet.

Panobinostat: Panobinostat will be administered orally.
Eligibility criteria:
Inclusion Criteria:

Ability and willingness to provide informed consent
HIV-1 infection prior to entry
Receiving suppressive ART therapy for a minimum of 24 consecutive months prior to screening with no interruption of therapy (same ART regimen for at least 12 weeks prior to screening)
Documented suppressed HIV-1 RNA (plasma HIV-1 RNA values <50 copies/ml)
CD4 T cell count ≥ 400 cells/mm3
Negative Hepatitis B surface antigen (HBsAg) or Negative HBV DNA PCR
Negative anti-Hepatitis C virus antibodies (anti-HCV) or negative HCV PCR if anti-HCV antibodies are positive
Negative TB Test (if positive, completed a recommended treatment course for latent TB)
Vaccinated for pneumococcal disease within last 5 years
No clinically significant eye disease
No evidence of clinical coronary heart disease
Not pregnant, planning to become pregnant, or breastfeeding
Willingness to continue to use contraceptives for 90 days after completing treatment
If male, willingness to use a condom during intercourse while taking panobinostat and total of 80 hours after stopping treatment
Not pregnant, planning to become pregnant, or breastfeeding
No evidence of coronary heart disease

Exclusion Criteria:

HIV-1 RNA > 50 copies/mL within 24 months of screening
Severe psychiatric disease, chronic liver disease, past or current evidence of immunologically mediated disease
Severe retinopathy due to diabetes, hypertension, cytomegalovirus or macular degeneration
Evidence of coronary heart disease
History of active thyroid disease requiring medication
Breastfeeding
Presence of a bacterial, fungal, viral or protozoal infection requiring systemic anti-infective therapy
Uncontrolled seizure disorders
History or other evidence of severe illness or other conditions
History of malignancy of any organ system within the past 5 years
Female participants who are pregnant or nursing
History of solid organ transplantation with an existing functional graft
Use of any immunomodulatory agents within 30 days prior to study enrollment or planned use during the trial
Active drug or alcohol use or dependence
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant in case of participation in the study
Use of HIV protease inhibitor or other strong or moderately strong CYP3A4 inhibitors
History of anaphylaxis, allergy or serious adverse reactions to Interferon-alpha2a/Interferon-alpha2b or panobinostat
Has taken: interleukins, systemic interferons or systemic chemotherapy
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: Standard of Care

Artificial Tears: Standard of care
Eligibility criteria:
Inclusion Criteria:

Age: Patients will be 18 years and older.
Duration of pink eye symptoms: No more than 4 days in first affected eye Positive immunoassay test "AdenoPlus(TM)" for presence of adenovirus.
Sex: "Pink eye" {adenoviral conjunctivitis (Ad-Cs)} occurs with equal prevalence in males and females, therefore we will recruit both genders.
Race/Ethnicity: Individuals of all races and ethnicities will be invited to participate in this study. Patient recruitment will reflect the distribution of race/ethnicity demographics for the patient population specific to each study site.

Exclusion Criteria:

Patients with history of herpes simplex infection or corneal ulceration
Eye surgery in the last 3 months
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty

1.3% Liposomal Bupivacaine: local tissue infiltration of Liposomal Bupivacaine during surgery
Eligibility criteria:
Inclusion Criteria:

Patients undergoing shoulder arthroplasty under general anesthesia
Patients undergoing open reduction internal fixation (ORIF) of a proximal humerus fracture under general anesthesia
Patients with American Society of Anesthesiologist (ASA) physical status classification of 1-3
Patients meeting criteria for standard of care continuous peripheral nerve block (CPNB) per anesthesia guidelines.
Patients agreeing to be available for brief follow up telephone survey post- operatively and being mentally able to respond.
Patients available for follow up routine post-operative clinic visits, per standard of care.

Exclusion Criteria:

Contraindications to regional anesthesia
Significant peripheral neuropathy or neurological disorder affecting the upper extremity
Contraindication to a component of multimodal analgesia
Pregnancy
Opioid tolerance
Cognitive or psychiatric condition that might affect patient assessment and/or inability to provide informed consent.
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 36
Group description: Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .

0.125% Bupivacaine: Continues nerve block with Bupivacaine during surgery and postoperatively
Eligibility criteria:
Inclusion Criteria:

Patients undergoing shoulder arthroplasty under general anesthesia
Patients undergoing open reduction internal fixation (ORIF) of a proximal humerus fracture under general anesthesia
Patients with American Society of Anesthesiologist (ASA) physical status classification of 1-3
Patients meeting criteria for standard of care continuous peripheral nerve block (CPNB) per anesthesia guidelines.
Patients agreeing to be available for brief follow up telephone survey post- operatively and being mentally able to respond.
Patients available for follow up routine post-operative clinic visits, per standard of care.

Exclusion Criteria:

Contraindications to regional anesthesia
Significant peripheral neuropathy or neurological disorder affecting the upper extremity
Contraindication to a component of multimodal analgesia
Pregnancy
Opioid tolerance
Cognitive or psychiatric condition that might affect patient assessment and/or inability to provide informed consent.
Intervention: FLUOCINOLONE ACETONIDE
Trial phase: Phase 4
ATC code: C05AA10 | D07AC04 | D07BC02 | D07CC02 | S01BA15 | S01CA10 | S02BA08 | S02CA05
SMILES: [H][C@@]12C[C@@]3([H])OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy

ILUVIEN
Eligibility criteria:
Inclusion Criteria:

Patients ≥18 years of age, of either sex that have signed informed consent / been well informed by the treating physician.
DME based on investigator's clinical evaluation and demonstrated using fundoscopic photography and spectral domain OCT.
Mean central foveal thickness (central subfield thickness) ≥350 microns in the study eye as measured using spectral domain OCT.
Vision impairment (20/60 to 20/400 using Snellen visual acuity equivalent) related to DME.
Previous treatment in the study eye with laser photocoagulation for DME, including focal/grid and pan-retinal, at least 3 months prior to the screening visit and ≥3 monthly anti-VEGF treatments (group 1).
Previous treatment in the study eye with laser photocoagulation for DME at least 3 months prior to the screening visit (group 2) and treatment with an intraocular anti-VEGF therapy not possible.
Patients considered as insufficiently responsive to prior therapy for DME, as defined by the study physician.

Exclusion Criteria:

IOP >21 mmHg at screening in the study eye.
Historical rise in IOP >25 mmHg following treatment with an intravitreal corticosteroid in the study eye.
Use of ≥2 IOP-lowering medications to control IOP at screening in the study eye.
Patients that have vitreomacular traction in DME and opaque media in the study eye.
Patients with severe proliferative diabetic retinopathy requiring pan retinal photocoagulation in the study eye.
Pregnant or breastfeeding.
Patients diagnosed with active angiographic central vein ischaemia prior to screening in the study eye.
Patients that have received pan retinal photocoagulation or undergone cataract surgery in the 3 months prior to the study start date in the study eye.

Patients with contraindications according to the current SPC:

The presence of pre-existing glaucoma.
Active or suspected ocular or periocular infection.
The patient is hypersensitive to the active agent or to one of the excipients.
Intervention: Dronabinol
Trial phase: Phase 4
ATC code: A04AD10
SMILES: [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)Oc1cc(CCCCC)cc(O)c12
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 85
Group description: In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning

Dronabinol: Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
Eligibility criteria:
Inclusion Criteria:

age 21-45
right-handed
free of lifetime diagnosis of Axis I psychiatric disorder
must be able to given informed consent
must be medically and neurologically healthy.

Exclusion Criteria:

any current medical condition requiring psychoactive/psychotropic medication or medication that would interact with dronabinol or interfere with study procedures
current or past allergic or adverse reaction or known sensitivity to cannabinoid-like substance (Dronabinol /Marijuana/Cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide.)
any current or past Axis I psychiatric disorder, including alcohol/substance abuse or dependence disorder
less than a high school education
lack of fluency in English
night shift work
currently pregnant or planning pregnancy or lactating (women)
unwilling/unable to sign informed consent document
inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia), as determined by self-report and a preliminary session in a mock scanner
left-handed
presence of ferrous-containing metals within the body (e.g., aneurysm clips,shrapnel/retained particles)
under 21 or over 45 years of age
anticipation of a required drug test in the 4 weeks following the study. No vulnerable participant populations will be included in this study
participation in an experiment involving shocks in the last 6 months.
Intervention: Cysteamine Bitartrate
Trial phase: Phase 2
SMILES: NCCS.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 22
Group description: Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.
Eligibility criteria:
Inclusion Criteria:

Completed all visits in Study RP103-MITO-001 (NCT02023866).
Body weight ≥ 5 kg.
The subject must be willing to abstain from initiating dietary supplements and non-prescribed medications except as allowed by the Investigator, throughout the study (from Day 1 to Study Exit).
Willing and able to comply with study drug dosing requirements, i.e. ingest the RP103 capsules intact, or sprinkled in liquid or soft food, or using a G-tube.

Sexually active female subjects of childbearing potential (i.e., not surgically sterile [tubal ligation, hysterectomy, or bilateral oophorectomy]) must agree to utilize two of the following acceptable forms of contraception throughout the study (from Day 1 to Study Exit):

Hormonal contraception: birth control pills, injection, patch, vaginal ring or implant;
Condom or diaphragm, with spermicide;
Intrauterine device (IUD);
Sterile male partner (vasectomy performed at least 6 months prior to the study).
Patient's legally authorized representative must provide written informed consent; Patient must provide assent, if required by local/institutional requirements.

Exclusion Criteria:

Documented diagnosis of concurrent inborn errors of metabolism.
Platelet count, lymphocyte count or hemoglobin below the lower limit of normal (LLN) at the Baseline visit.
Hepatic insufficiency with liver enzyme tests (alkaline phosphatase, aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than 2.5 times the upper limit of normal (ULN) at the Baseline Visit.
Bilirubin > 1.2 g/dL at the Baseline Visit.
Inability to complete the elements of the study, e.g., coma, hemodynamic instability or requiring continuous ventilator support.
Malabsorption requiring total parenteral nutrition (TPN), chronic diarrhea, bouts of pseudo obstruction.
Severe end-organ hypo-perfusion syndrome secondary to cardiac failure resulting in lactic acidosis.
Patients with suspected elevated intracranial pressure, pseudotumor cerebri (PTC) and/or papilledema.
Severe gastrointestinal disease including gastroparesis.
History of drug or alcohol abuse.
History of pancreatitis.
Participated in an investigational drug trial (except the RP103-MITO-001 study) within 30 days or, within 90 days for a biologic, device, or surgical treatment, for inherited mitochondrial diseases prior to the Baseline Visit.
Known or suspected hypersensitivity to cysteamine and penicillamine.
Female subjects who are nursing, planning a pregnancy, known or suspected to be pregnant, or with a positive serum pregnancy test at the Baseline visit.
Patients who, in the opinion of the Investigator, are not able or willing to comply with the protocol.
Intervention: Maleic Acid
Trial phase: Phase 3
ATC code: D05AX01
SMILES: O=C(O)/C=C/C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 95
Group description: Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dose-titrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.
Eligibility criteria:
Inclusion Criteria:

Men or women must be at least 18 years of age at the time of screening
Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization Patients with moderate to severe plaque psoriasis who are candidates for systemic therapy as defined at randomization by:
PASI score of >10
Affected body surface area (BSA) > 10%
DLQI >10
Inadequate response, intolerance or contraindication to topical psoriasis treatment as documented in the patient's medical history or reported by the patient or determined by the investigator at screening.

Exclusion Criteria (abbreviated):

Previous systemic treatment of plaque psoriasis or known contraindication for systemic therapy at baseline
Ongoing use of other prohibited psoriasis and non-psoriasis treatment.
Clinically important active infections or infestations, chronic, recurrent or latent infections or infestations
Patients with severe liver diseases
Patients with severe gastrointestinal diseases including but not limited to ventricular and duodenal ulcers
Patients with severe kidney diseases or serum creatinine above 1 x ULN
Patients with known hematological disease or lab abnormalities
Pregnancy, breast feeding, or unwillingness/inability to use appropriate measures of contraception (if necessary)
Intervention: Estradiol
Trial phase: Phase 2
ATC code: G02BB01 | G03AA14 | G03AA17 | G03AB08 | G03CA03 | G03CA53 | G03EA01 | G03EA02 | G03EA03 | G03FA01 | G03FA02 | G03FA03 | G03FA04 | G03FA05 | G03FA06 | G03FA07 | G03FA08 | G03FA09 | G03FA10 | G03FA11 | G03FA12 | G03FA13 | G03FA14 | G03FA15 | G03FA16 | G03FA17 | G03FB01 | G03FB02 | G03FB03 | G03FB04 | G03FB05 | G03FB06 | G03FB07 | G03FB08 | G03FB09 | G03FB10 | G03FB11 | G03FB12 | G03HB01 | H01CC53 | H01CC54
SMILES: [H][C@@]12CCc3cc(O)ccc3[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 11
Group description: 6 months of estradiol 0.045mg/levonorgestrel 0.015mg (once weekly patch).

estradiol 0.045 mg/levonorgestrel 0.015mg
Eligibility criteria:
Inclusion Criteria:

Female; ages 25-50 years
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) psychiatric criteria for AN, including <85% of ideal body weight as defined by the 1983 Metropolitan Life Insurance Height and Weight Tables, and amenorrhea
T-score of < -1.5 at spine or hip
Treatment team or treatment professional in place for clinical treatment/monitoring during the study

Exclusion Criteria:

Diseases known to affect bone metabolism, including untreated thyroid dysfunction, vitamin D deficiency, Cushing's syndrome, diabetes mellitus or renal insufficiency
Personal history of venous or arterial clot
History of stroke or myocardial infarction
History of migraine headaches
History of hypercoagulable disorder
Personal history or history of a first-degree relative with breast cancer
History of hereditary angioedema
Any medication known to affect bone metabolism, including systemic glucocorticoids within three months of the baseline visit, depot medroxyprogesterone within 6 months of the baseline visit, oral bisphosphonates within one year of the baseline visit or intravenous (IV) bisphosphonates within three years of the baseline visit
Bone fracture within the prior 12 months
Serum potassium < 3.0 meq/L or serum alanine aminotransferase (ALT) > 3 times the upper limit of normal
Fasting serum triglyceride level > 150 mg/dL
Pregnant or breastfeeding
Active substance abuse
Intervention: Resveratrol
Trial phase: Phase 4
SMILES: Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 40mg of resveratrol

Resveratrol: 40mg of resveratrol (powder)
Eligibility criteria:
Inclusion Criteria:

Endometriosis diagnosed by laparoscopy

Exclusion Criteria:

Known allergy to resveratrol
Use of gonadotropin or danazol in the last month
Intervention: Vorapaxar Sulfate
Trial phase: Phase 2
SMILES: CCOC(=O)NC1CCC2C(C1)CC1C(=O)OC(C)C1C2C=Cc1ccc(-c2cccc(F)c2)cn1.O=S(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Participants were randomized to receive vorapaxar sulfate for 12 weeks (2.08 mg orally once daily).
Eligibility criteria:
Inclusion Criteria:

Age >18
Receiving or planning to receive maintenance hemodialysis
Ability to sign informed consent
3 mm venous diameter within recipient vein

Exclusion Criteria:

History of stroke, transient ischemic attack or intracranial hemorrhage
History of or high level of suspicion for, severe arterial insufficiency of the hand
Indication or ongoing therapy with other antiplatelet agents, other than aspirin 81 mg daily
Indication or ongoing therapy with anticoagulants, including warfarin, low molecular weight heparin, factor Xa inhibitors or direct thrombin and other inhibitors.